

chain nodes :
7 8 10 11 27 28 29 30
ring nodes :
1 2 3 4 5 6 9 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-7 3-10 7-8 8-9 10-11 11-12 13-30 15-29 18-21 20-28 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-17 9-20 12-13 12-16 13-14 14-15 15-16 17-18
18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-2 1-6 1-7 2-3 3-4 4-5 5-6 7-8 9-17 9-20 12-13 12-16 13-14 13-30
14-15 15-16 15-29 17-18 18-19 19-20 20-28
exact bonds :
3-10 8-9 10-11 11-12 18-21 24-27
normalized bonds :
21-22 21-26 22-23 23-24 24-25 25-26

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS
29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:44:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:44:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     51 TO ITERATE

100.0% PROCESSED       51 ITERATIONS                               19 ANSWERS
SEARCH TIME: 00.00.01

L3           19 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     161.33     161.54

FILE 'CAPLUS' ENTERED AT 09:44:29 ON 17 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Aug 2005  VOL 143 ISS 8
FILE LAST UPDATED: 16 Aug 2005  (20050816/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L4            1 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:740322 CAPLUS
DOCUMENT NUMBER: 141:260738
TITLE: Preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes
INVENTOR(S): Gretzke, Dirk; Glombik, Heiner; Falk, Eugen; Goerlitzer, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076447	A1	20040910	WO 2004-EP1585	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308354	A1	20041223	DE 2003-10308354	20030227
US 2004198786	A1	20041007	US 2004-789865	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308354 A	20030227
			US 2003-487432P P	20030715

OTHER SOURCE(S): MARPAT 141:260738
GI



I

II

AB Title compds. I [R = (un)substituted Ph, annulated Ph; R1 = H, CF3, alkyl, alkoxy, cycloalkyl, Ph; R2 = (un)substituted Ph, oxoheterocyclyl; X = alkanadiyl, oxaalkanediyl; X1 = cycloalkanediyl, cycloalkenediyl, oxacyclalkanediyl, oxacycloalkenediyl; Y = (un)substituted alkanadiyl, alkenediyl] were prepared for treating and/or preventing disturbances of fatty acid metabolism, impaired glucose utilization, and disturbances in which insulin resistance plays a role. Thus, 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole was treated with 1,3-cyclohexanediol, followed by 3-O2NC6H4CH2Br to give the title compound II which had EC50 for activation of the PPARα receptor of 91 nM. Compds. I are claimed useful for the treatment of type II diabetes.

IT **755419-15-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755419-15-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **755420-03-2P 755420-08-7P 755420-15-6P 755420-21-4P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755420-03-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-08-7 CAPLUS

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-15-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-21-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **755418-98-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755418-98-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **755419-71-7P 755419-76-2P 755419-80-8P 755420-26-9P 755420-33-8P 755420-48-5P 755420-52-1P 755420-57-6P 755420-67-8P 755420-73-6P 755420-79-2P 755420-98-5P 755421-04-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755419-71-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-76-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-80-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-26-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-33-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-48-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 755420-79-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-98-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-methyl-5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755421-04-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-52-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-57-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-67-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-73-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.39	166.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'REGISTRY' ENTERED AT 09:44:40 ON 17 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2005 HIGHEST RN 860495-66-5
DICTIONARY FILE UPDATES: 16 AUG 2005 HIGHEST RN 860495-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *

chain nodes :
7 8 10 22
ring nodes :
1 2 3 4 5 6 9 11 12 13 14 15 16 17 18 19 20 21 26 27 28 29
chain bonds :
1-7 3-10 7-8 8-9 10-11 13-16 15-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-12 9-15 11-26 11-29 12-13 13-14 14-15 16-17
16-21 17-18 18-19 19-20 20-21 26-27 27-28 28-29
exact/norm bonds :
1-2 1-6 1-7 2-3 3-4 3-10 4-5 5-6 7-8 8-9 9-12 9-15 10-11 11-26 11-29
12-13 13-14 13-16 14-15 15-22 26-27 27-28 28-29
normalized bonds :
16-17 16-21 17-18 18-19 19-20 20-21

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 26:Atom 27:Atom 28:CLASS 29:Atom

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             7 TO      298
PROJECTED ANSWERS:                1 TO       80

L6            1 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 09:45:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    108 TO ITERATE

100.0% PROCESSED      108 ITERATIONS                          52 ANSWERS
SEARCH TIME: 00.00.01

L7           52 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 161.33     328.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -0.73

FILE 'CAPLUS' ENTERED AT 09:45:10 ON 17 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:740322 CAPLUS
DOCUMENT NUMBER: 141:260738
TITLE: Preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes
INVENTOR(S): Gretzke, Dirk; Glombik, Heiner; Falk, Eugen; Goerlitzer, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076447	A1	20040910	WO 2004-EP1585	20040219
W: AE, AE, AG, AL, AL, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308354	A1	20041223	DE 2003-10308354	20030227
US 2004198786	A1	20041007	US 2004-789865	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308354 A	20030227
			US 2003-487432P P	20030715

OTHER SOURCE(S): MARPAT 141:260738
GI



I

II

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [R = (un)substituted Ph, annulated Ph; R1 = H, CF3, alkyl, alkoxy, cycloalkyl, Ph; R2 = (un)substituted Ph, oxoheterocyclyl; X = alkanadiyl, oxaalkanediyl; X1 = cycloalkanediyl, cycloalkenediyl, oxacycloalkanediyl, oxacycloalkenediyl; Y = (un)substituted alkanadiyl, alkenediyl] were prepared for treating and/or preventing disturbances of fatty acid metabolism, impaired glucose utilization, and disturbances in which insulin resistance plays a role. Thus, 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole was treated with 1,3-cyclohexanediol, followed by 3-O2NC6H4CH2Br to give the title compound II which had EC50 for activation of the PPARα receptor of 91 nM. Compds. I are claimed useful for the treatment of type II diabetes.

IT **755419-15-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755419-15-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **755419-93-3P 755419-98-8P 755420-03-2P 755420-08-7P 755420-15-6P 755420-21-4P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755419-93-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755419-98-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-03-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-08-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-15-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 755420-21-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **755418-86-1P 755418-92-9P 755418-98-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755418-86-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755418-92-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 755418-98-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 755419-05-7P 755419-10-4P 755419-27-3P
755419-43-3P 755419-49-9P 755419-54-6P
755419-61-5P 755419-65-9P 755419-71-7P
755419-76-2P 755419-80-8P 755419-87-5P
755420-26-9P 755420-33-8P 755420-38-3P
755420-42-9P 755420-48-5P 755420-52-1P
755420-57-6P 755420-63-4P 755420-67-8P
755420-73-6P 755420-79-2P 755420-82-7P
755420-87-2P 755420-93-0P 755420-98-5P
755421-04-6P 755421-09-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylmethoxycyclohexanols as PPARα agonists for the treatment of type II diabetes)

RN 755419-05-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-10-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 755419-54-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-61-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-65-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-27-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-43-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-[3,5-bis(trifluoromethyl)phenyl]-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-49-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 755419-71-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-76-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-80-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-87-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-26-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-33-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-38-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-42-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-48-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-52-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-57-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-67-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-73-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-79-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-82-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 755420-87-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-93-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-98-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-methyl-5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755421-04-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 755421-09-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:149264 CAPLUS
DOCUMENT NUMBER: 136:340623
TITLE: Novel 5-Substituted 2,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insulin Sensitizers with Antidiabetic Activities
AUTHOR(S): Momose, Yu; Maekawa, Tsuyoshi; Yamano, Tohru; Kawada, Mitsuru; Odaka, Hiroyuki; Ikeda, Hitoshi; Sohda, Takashi
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories II, Pharmacology Research Laboratories II, and Strategic Research Planning, Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Yodogawaku, Osaka, 532-8686, Japan
SOURCE: Journal of Medicinal Chemistry (2002), 45(7), 1518-1534
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:340623
GI



I

AB 5-(ω-Azolylalkoxyphenylalkyl)-2,4-thiazolidinones and -2,4-oxazolidinones such as furylmethyloxazolylmethoxymethoxyphenylpropyl oxazolidinedione I were prepared as potential antidiabetic and antihyperlipidemic agents. Many of the 2,4-thiazolidinediones and 2,4-oxazolidinones showed potent glucose- and lipid-lowering activities. The antidiabetic activities of the 2,4-oxazolidinediones were superior to those of the 2,4-thiazolidinediones. Both enantiomers of I, one of the most interesting compds. in terms of activity, were synthesized by using an asym. O-acetylation of the corresponding α-hydroxyvalerate with immobilized lipase, followed by cyclization of the oxazolidinedione ring. The (R)-(+)-enantiomer of I showed more potent glucose-lowering activity [ED25 = 0.561 mg/kg/d] than either the (S)-(-)-enantiomer (ED25 > 1.5 mg/kg/d) or pioglitazone (ED25 = 6 mg/kg/d) in KKAy mice. (+)-(R)-I also exhibited a 10-fold more potent antidiabetic activity (ED25 = 0.05 mg/kg/d) than pioglitazone (ED25 = 0.5 mg/kg/d) in Wistar fatty rats. The antidiabetic effects of I are related to its activity as a potent agonist for peroxisome proliferator-activated receptor γ (PPAR-γ) (EC50 = 8.87 nM). The crystal structures of intermediates in the synthesis of nonracemic thiazolidinediones were determined by X-ray crystallog.

IT 417729-31-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 5-(ω-azolylalkoxyphenylalkyl)-2,4-thiazolidinones and -2,4-oxazolidinediones as peroxisome proliferator-activated receptor

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
γ agonists and as potential antidiabetic and antihyperlipidemic agents)
RN 417729-31-8 CAPLUS
CN 2,4-Oxazolidinedione, 5-[3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:94931 CAPLUS
DOCUMENT NUMBER: 132:265154
TITLE: New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties
AUTHOR(S): Malamas, Michael S.; Sredy, Janet; Gunawan, Iwan; Mihan, Brenda; Sawicki, Diane R.; Seestaller, Laura; Sullivan, Donald; Flam, Brenda R.
CORPORATE SOURCE: Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(5), 995-1010
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be neg. regulators of the insulin receptor. Inhibition of PTPases may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compds. were potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the mol. as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones (E)- and (Z)-I [R = H, CH2CO2H] were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 μM. Several compds. normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.

IT **174259-09-7P 174259-13-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenyloxazolylalkoxyphenylalkyloxazolidinediones as protein tyrosine phosphatase inhibitors)

RN 174259-09-7 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 174259-13-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **174259-10-0P 174259-11-1P 174259-12-2P 174259-14-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of phenyloxazolylalkoxyphenylalkyloxazolidinediones as protein tyrosine phosphatase inhibitors)

RN 174259-10-0 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(2,2,2-trifluoroethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-11-1 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 174259-12-2 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-14-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:155097 CAPLUS
DOCUMENT NUMBER: 126:157496
TITLE: Preparation of oxazolidinediones and analogs as antitumor agents
INVENTOR(S): Sohda, Takashi; Matsutani, Etsuya; Momose, Yu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700249	A1	19970103	WO 1996-JP1643	19960614
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, XG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 09136877	A2	19970527	JP 1996-107989	19960426
AU 9660168	A1	19970115	AU 1996-60168	19960614
PRIORITY APPLN. INFO.:			JP 1995-150048 A	19950616
			JP 1995-234235 A	19950912
			JP 1996-107989 A	19960426
			WO 1996-JP1643 W	19960614

OTHER SOURCE(S): MARPAT 126:157496
GI



I



II

AB Title compds. [I; R = (un)substituted hydrocarbyl; R1 = H; R2 = CHR3Z1R4; R3 = H; R1R3 = bond; R4 = (un)substituted hydroxyphenyl, -hydrocarbyloxyphenyl, -2-hydroxypyridyl, etc.; X = O or S; Z = O, S, (alkyl)imino; Z1 = hydrocarbylene] were prepared Thus, 4-

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

isopropoxy-3-methoxycinnamaldehyde (prepn. given) was condensed with 2,4-oxazolidinedione and the hydrogenated and deprotected product etherified and N-alkylated in successive steps by 4-chloromethyl-2-[(E)-2-phenylethenyl]oxazole (prepn. given) to give title compd. II. Data for biol. activity of I were given.

IT **186894-91-7P 186894-92-8P 186894-99-5P**
186895-00-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinediones and analogs as antitumor agents)

RN 186894-91-7 CAPLUS

CN 2,4-Oxazolidinedione, 5-[2-[4-methoxy-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-3-[3-(4-phenyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186894-92-8 CAPLUS

CN 2,4-Oxazolidinedione, 5-[2-[4-methoxy-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-3-[3-(4-phenyl-1-piperazinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



IT **186894-28-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinediones and analogs as antitumor agents)

RN 186894-28-0 CAPLUS

CN 2,4-Oxazolidinedione, 5-[2-[4-methoxy-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 186894-99-5 CAPLUS

CN 2,4-Oxazolidinedione, 5-[2-[3-[[2-[3,5-bis(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-4-methoxyphenyl]ethyl]-3-[3-(4-phenyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186895-00-1 CAPLUS

CN 2,4-Oxazolidinedione, 5-[2-[3-[[2-[3,5-bis(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-4-methoxyphenyl]ethyl]-3-[3-(4-phenyl-1-piperazinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:452768 CAPLUS
DOCUMENT NUMBER: 125:142746
TITLE: Oxa(thia)diazolidinediones and oxa(thia)zolidinediones as antihyperglycemic agents
INVENTOR(S): Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 421,167.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5532256	A	19960702	US 1995-457948	19950601
US 5468762	A	19951121	US 1994-245734	19940518
PRIORITY APPLN. INFO.:			US 1994-245734	A3 19940518
			US 1995-421167	A2 19950413

OTHER SOURCE(S): MARPAT 125:142746
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to novel compds. which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models of non-insulin dependent diabetes mellitus (NIDDM or Type II diabetes). These compds. have the formula I wherein: R1 is C1-C6 alkyl, C3-C8 cycloalkyl, thienyl, furyl, pyridyl, R10C6H4 or R10C10H6 where R10 is hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, iodine, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1-C6 alkyl; X is O or S; n is 0, 1, or 2; A is II or III where R3 is hydrogen, C1-C6 alkyl, halogen, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is IV-VI where R4 is hydrogen, C1-C6 alkyl, allyl, C6-C10 aryl, C6-C10 aryl-(CH2)1-6, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3-C8 cycloalkyl; R5 is hydrogen, C1-C6 alkyl, C6-C10 aryl, or C6-C10 aryl-(CH2)1-6; m is 0, 1, or 2; R6 is hydrogen or C1-C6 alkyl; R7 is hydrogen or C1-C6 alkyl; R8 and R9 are selected independently from hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is S; Z is N or CH; or a pharmaceutically acceptable salt thereof. Thus, alkylation of 3-hydroxylbenzaldehyde with 4-chloromethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole afforded 65% 3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]benzaldehyde; reaction of the latter with ethylmagnesium bromide followed by oxidation afforded 74% 1-(3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl)propan-1-one; condensation with tri-Et phosphonoacetate afforded 55% trans- and 28% cis-3-(3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl)pent-2-enoic acid Et ester; reduction of the trans isomer to the (E) pent-2-en-1-ol (91%) followed by condensation with BOC-HNO-BOC afforded 96% (E)-N-tert-butoxycarbonyloxy-(3-(3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl)pent-2-enyl)carbamic acid tert-Bu ester; deprotection to the hydroxylamine (88%) followed by cyclization with N-(chlorocarbonyl) isocyanate afforded 64% (E)-2-(3-(3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]pent-2-enyl)[1,2,4]oxadiazolidine-3,5-dione VII which exhibited -76% change in blood glucose in db/db mice at 100 mg/kg p.o.

IT **174259-09-7P 174259-10-0P 174259-11-1P**

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
174259-12-2P 174259-13-3P 174259-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxa(thia)diazolidinediones and oxa(thia)zolidinediones as antihyperglycemic agents)

RN 174259-09-7 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-10-0 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(2,2,2-trifluoroethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-11-1 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-12-2 CAPLUS

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-13-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-14-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:428416 CAPLUS
DOCUMENT NUMBER: 125:86639
TITLE: Preparation of oxazolidinedione derivatives having excellent actions of lowering blood sugar and lipid in blood
INVENTOR(S): Sohda, Takashi; Odaka, Hiroyuki; Momose, Yu; Kawada, Mitsuru
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 710659	A1	19960508	EP 1995-307793		19951101
EP 710659	B1	20040128			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
TW 403748	B	20000901	TW 1995-84111412		19951028
US 5932601	A	19990803	US 1995-550289		19951030
ZA 9509204	A	19970430	ZA 1995-9204		19951031
JP 09124623	A2	19970513	JP 1996-298847		19951031
JP 09194467	A2	19970729	JP 1995-284106		19951031
JP 2850809	B2	19990127			
CA 2161944	AA	19960503	CA 1995-2161944		19951101
FI 9505235	A	19960503	FI 1995-5235		19951101
NO 9504369	A	19960503	NO 1995-4369		19951101
NO 306401	B1	19991101			
AU 9536607	A1	19960509	AU 1995-36607		19951101
AU 701847	B2	19990204			
HU 75101	A2	19970428	HU 1995-3116		19951101
BR 9505051	A	19971021	BR 1995-5051		19951101
RU 2144030	C1	20000110	RU 1995-118725		19951101
AT 258549	E	20040215	AT 1995-307793		19951101
CN 1129698	A	19960828	CN 1995-121558		19951102
PRIORITY APPLN. INFO.:			JP 1994-269826	A	19941102
			JP 1995-171768	A	19950707
			JP 1995-220942	A	19950829
			JP 1995-284106	A3	19951031

OTHER SOURCE(S): MARPAT 125:86639
GI



I

AB (Phenylalkyl)oxazolidinedione derivs. and analogs represented by the formula [I; R = optionally substituted hydrocarbon residue or heterocyclic group; Y = CO, OCH(OH) or NR3 (wherein R3 = optionally substituted alkyl group); m = 0 or 1; n = 0, 1 or 2; A = C1-7 divalent aliphatic hydrocarbon group; R1 = H or alkyl group; ring E = benzene ring having 1 or 2

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
substituents; L, M = H, or L and M may optionally be combined with each other to form a bond; with a proviso that the partial formula: does not include 2-alkylphenylene] or salts thereof, which are useful for the treatment of diabetes and hyperlipemia, are prepd. Thus, 3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)cinnamaldehyde was condensed with 2,4-oxazolidinedione in the presence of piperidine in refluxing AcOH followed by catalytic hydrogenation over 5% Pd-C in THF to give 5-[3-[3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propyl]-2,4-oxazolidinedione (II). II mixed in a powdery feed at 0.005% was fed to KKAy mice freely for 4 days and blood was collected from the orbital venous plexus and analyzed to show 57% hypoglycemic action and 75% triglyceride-lowering action as compared to the control animals. A tablet formulation contg. II was given.

IT 178610-07-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinedione derivs. for therapy in lowering sugar and
lipid in blood)

RN 178610-07-6 CAPLUS
CN 2,4-Oxazolidinedione, 5-[3-[4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:1003034 CAPLUS
DOCUMENT NUMBER: 124:202232
TITLE: Oxazolyl azolidinediones as antihyperglycemic agents
INVENTOR(S): Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5468762	A	19951121	US 1994-245734	19940518
CA 2190015	AA	19951123	CA 1995-2190015	19950413
WO 9531454	A1	19951123	WO 1995-US4631	19950413
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9523842	A1	19951205	AU 1995-23842	19950413
AU 684357	B2	19971211		
US 5510360	A	19960423	US 1995-421111	19950413
EP 759919	A1	19970305	EP 1995-916989	19950413
EP 759919	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1152312	A	19970618	CN 1995-194037	19950413
HU 76823	A2	19971128	HU 1996-3185	19950413
JP 10500133	T2	19980106	JP 1995-529644	19950413
AT 173256	E	19981115	AT 1995-916989	19950413
ES 2124545	T3	19990201	ES 1995-916989	19950413
ZA 9503981	A	19961118	ZA 1995-3981	19950516
US 5532256	A	19960702	US 1995-457948	19950601

PRIORITY APPLN. INFO.: US 1994-245734 A 19940518
US 1995-421167 A2 19950413
WO 1995-US4631 W 19950413

OTHER SOURCE(S): MARPAT 124:202232
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to compds. which have oral antihyperglycemic activity of the formula I wherein: R1 is, e.g., C1-C6 alkyl, C3-C8 cycloalkyl, thienyl, furyl, pyridyl, R10-substituted Ph or naphthyl where R10 is hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, iodine, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1-C6 alkyl; X is O or S; n is 1 or 2; A is II or III where R3 is hydrogen, C1-C6 alkyl, halogen, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is IV, V, or VI where R4 is hydrogen, C1-C6 alkyl, allyl, C6-C10 aryl, C6-C10-aryl-(CH2)1-6, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3-C8 cycloalkyl; R5 is hydrogen, C1-C6 alkyl, C6-C10 aryl, or C6-C10-aryl-(CH2)1-6 ; m is 0, 1, or 2; R6 is hydrogen or C1-C6 alkyl; R7 is hydrogen or C1-C6 alkyl; R8 and R9 are selected independently from hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is O or S; Z is N or CH when Y is O and Z is CH when Y is S; or a pharmaceutically acceptable salt thereof. Thus, e.g., treatment of (E)-N-(3-[3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]pent-2-enyl)hydroxylamine (prepn. given) with N-(Chlorocarbonyl)isocyanate afforded 64% (E)-2-(3-[3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]pent-2-enyl)[1,2,4]oxadiazolidine-3,5-dione (VII) which exhibited -76% change in blood glucose in diabetic db/db mice at 100 mg/kg p.o.

IT **174259-09-7P 174259-10-0P 174259-11-1P**
174259-12-2P 174259-13-3P 174259-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxazolyl azolidinediones as antihyperglycemic agents)

RN 174259-09-7 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-10-0 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(2,2,2-trifluoroethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-11-1 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 174259-12-2 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-13-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-14-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2E)-3-[3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)